347 related articles for article (PubMed ID: 30916598)
1. Oncologic therapies associated with cardiac toxicities: how to minimize the risks.
Cardinale D; Stivala F; Cipolla CM
Expert Rev Anticancer Ther; 2019 May; 19(5):359-374. PubMed ID: 30916598
[TBL] [Abstract][Full Text] [Related]
2. Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy.
Cardinale D; Biasillo G; Salvatici M; Sandri MT; Cipolla CM
Expert Rev Mol Diagn; 2017 Mar; 17(3):245-256. PubMed ID: 28092472
[TBL] [Abstract][Full Text] [Related]
3. The role of cardiac biomarkers in cardio-oncology.
Riddell E; Lenihan D
Curr Probl Cancer; 2018 Jul; 42(4):375-385. PubMed ID: 30126650
[TBL] [Abstract][Full Text] [Related]
4. Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.
Cardinale D; Biasillo G; Cipolla CM
Curr Cardiol Rep; 2016 Jun; 18(6):51. PubMed ID: 27108361
[TBL] [Abstract][Full Text] [Related]
5. Assessment of cardiotoxicity with cardiac biomarkers in cancer patients.
Cardinale D; Cipolla CM
Herz; 2011 Jun; 36(4):325-32. PubMed ID: 21562775
[TBL] [Abstract][Full Text] [Related]
6. Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity.
O'Hare M; Murphy K; Mookadam F; Sharma A; Lee H
Expert Rev Cardiovasc Ther; 2015 May; 13(5):519-27. PubMed ID: 25864865
[TBL] [Abstract][Full Text] [Related]
7. Role of biomarkers in chemotherapy-induced cardiotoxicity.
Cardinale D; Sandri MT
Prog Cardiovasc Dis; 2010; 53(2):121-9. PubMed ID: 20728699
[TBL] [Abstract][Full Text] [Related]
8. Identifying cancer patients at risk for cardiotoxicity.
Salvatici M; Sandri MT
Future Oncol; 2015; 11(14):2077-91. PubMed ID: 26198838
[TBL] [Abstract][Full Text] [Related]
9. Update on Incorporating Biomarkers with Imaging Findings for the Detection and Management of Cardiotoxicity.
Quatromoni N; Scherrer-Crosbie M
Curr Cardiol Rep; 2018 Jun; 20(8):67. PubMed ID: 29931487
[TBL] [Abstract][Full Text] [Related]
10. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
[TBL] [Abstract][Full Text] [Related]
11. Role of biomarkers in cardioncology.
Cardinale D; Salvatici M; Sandri MT
Clin Chem Lab Med; 2011 Sep; 49(12):1937-48. PubMed ID: 21892906
[TBL] [Abstract][Full Text] [Related]
12. [Cardiotoxicity relatively common in cancer treatment].
Bühlmann Lerjen E; Hübbert L; Papakonstantinou A; Hedayati E; Linde C; Månsson Broberg A
Lakartidningen; 2016 Jun; 113():. PubMed ID: 27299327
[TBL] [Abstract][Full Text] [Related]
13. [Cardiotoxicity of anticancer therapies. Towards the implementation of cardio-oncology units].
Hameau R; Gabrielli L; Garrido M; Guzmán AM; Retamal I; Vacarezza MJ; Greig D; Ocqueteau M; Sánchez C; Pizarro M; Corvalán A; Lavandero S; Castro PF; Martínez G
Rev Med Chil; 2018 Jan; 146(1):68-77. PubMed ID: 29806680
[TBL] [Abstract][Full Text] [Related]
14. The Role of Biomarkers to Evaluate Cardiotoxicity.
Upshaw JN
Curr Treat Options Oncol; 2020 Aug; 21(10):79. PubMed ID: 32767198
[TBL] [Abstract][Full Text] [Related]
15. Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues.
Bracun V; Aboumsallem JP; van der Meer P; de Boer RA
Curr Oncol Rep; 2020 Jun; 22(7):67. PubMed ID: 32514994
[TBL] [Abstract][Full Text] [Related]
16. An update on the risk prediction and prevention of anticancer therapy-induced cardiotoxicity.
Bhave M; Shah AN; Akhter N; Rosen ST
Curr Opin Oncol; 2014 Nov; 26(6):590-9. PubMed ID: 25233068
[TBL] [Abstract][Full Text] [Related]
17. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.
Virani SA; Dent S; Brezden-Masley C; Clarke B; Davis MK; Jassal DS; Johnson C; Lemieux J; Paterson I; Sebag IA; Simmons C; Sulpher J; Thain K; Thavendiranathan P; Wentzell JR; Wurtele N; Côté MA; Fine NM; Haddad H; Hayley BD; Hopkins S; Joy AA; Rayson D; Stadnick E; Straatman L
Can J Cardiol; 2016 Jul; 32(7):831-41. PubMed ID: 27343741
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies - Part 2.
Manolis AA; Manolis TA; Mikhailidis DP; Manolis AS
Expert Opin Drug Saf; 2018 Sep; 17(9):893-915. PubMed ID: 30126303
[TBL] [Abstract][Full Text] [Related]
20. Using cardiac biomarkers and treating cardiotoxicity in cancer.
Colombo A; Cardinale D
Future Cardiol; 2013 Jan; 9(1):105-18. PubMed ID: 23259478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
